FDA blesses Forest, Almirall COPD drug
This article was originally published in Scrip
Executive Summary
Forest Laboratories and Almirall won the US FDA's OK Tudorza Pressair (aclidinium bromide inhalation powder) as a long-term maintenance treatment for bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.